Influenza A Virus, H3N2 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 123 Published: April 29, 2022 Report Code: GMDGDHC22133IDB

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

The Influenza A Virus, H3N2 – drugs in development research report provides a comprehensive overview on the therapeutics under development for Influenza A Virus, H3N2, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 and features dormant and discontinued projects.

Key Targets in the Influenza A Virus, H3N2 Pipeline Drugs Market

The key targets in the Influenza A Virus, H3N2 pipeline drugs market are Hemagglutinin, Exo Alpha Sialidase, Hemagglutinin HA, 2019 Novel corona Virus Spike Glycoprotein, Hemagglutinin 1, Lipopolysaccharide, Substance P Receptor, Toll Like Receptor 2, Toll Like Receptor 3, and Toll Like Receptor 6.

Influenza A Virus, H3N2 Drugs Market, by Targets

Influenza A Virus, H3N2 Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Influenza A Virus, H3N2 Pipeline Drugs Market

The key mechanisms of action in the Influenza A Virus, H3N2 pipeline drugs market are Exo Alpha Sialidase Inhibitor, Hemagglutinin Inhibitor, Lipopolysaccharide Inhibitor, Substance P Receptor Agonist, Toll Like Receptor 2 Agonist, Toll Like Receptor 3 Agonist, and Toll Like Receptor 6 Agonist.

Influenza A Virus, H3N2 Pipeline Drugs Market, by MoA

Influenza A Virus, H3N2 Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Influenza A Virus, H3N2 Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Influenza A Virus, H3N2 pipeline drugs market are intramuscular, nasal, oral, intravenous, subcutaneous, inhalational, intradermal, parenteral, and transdermal.

Influenza A Virus, H3N2 Pipeline Drugs Market Analysis, by RoA

Influenza A Virus, H3N2 Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Influenza A Virus, H3N2 Pipeline Drugs Market

The key molecule types in the Influenza A Virus, H3N2 pipeline drugs market are Inactivated Vaccine, Small Molecule, Subunit Vaccine, Live Attenuated Vaccine, mRNA Vaccine, Recombinant Vector Vaccine, Monoclonal Antibody, Antibody, DNA Vaccine, and Fusion Protein among others.

Influenza A Virus, H3N2 Pipeline Drugs Market, by Molecule Type

Influenza A Virus, H3N2 Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Influenza A Virus, H3N2 Pipeline Drugs Market

The major companies in the Influenza A Virus, H3N2 pipeline drugs market are Sanofi, Adimmune Corp, FluGen Inc, Aphios Corp, CSL Ltd, Moderna Inc, NanoViricides Inc, and AbbVie Inc among others.

Influenza A Virus, H3N2 Pipeline Drugs Market, by Major Companies

Influenza A Virus, H3N2 Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Influenza A Virus, H3N2 Pipeline Drugs Market Overview

Key Targets Exo Alpha Sialidase, Hemagglutinin HA, 2019 Novel corona Virus Spike Glycoprotein, Hemagglutinin 1, Lipopolysaccharide, Substance P Receptor, Toll Like Receptor 2, Toll Like Receptor 3, and Toll Like Receptor 6
Key Mechanisms of Action Exo Alpha Sialidase Inhibitor, Hemagglutinin Inhibitor, Lipopolysaccharide Inhibitor, Substance P Receptor Agonist, Toll Like Receptor 2 Agonist, Toll Like Receptor 3 Agonist, and Toll Like Receptor 6 Agonist
Key Routes of Administration Intramuscular, Nasal, Oral, Intravenous, Subcutaneous, Inhalational, Intradermal, Parenteral, and Transdermal
Key Molecule Types Monoclonal Antibody, Small Molecule, Recombinant Protein, Fusion Protein, Modified Cell Therapy, Synthetic Peptide, and Biologic
Major Companies Sanofi, Adimmune Corp, FluGen Inc, Aphios Corp, CSL Ltd, Moderna Inc, NanoViricides Inc, and AbbVie Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H3N2 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Influenza A Virus, H3N2

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

AbbVie Inc

Adimmune Corp

Alla Chem LLC

Allergy Therapeutics Plc

AlphaVax Inc

Ansun Biopharma Inc

Aphios Corp

AstraZeneca Plc

AusBio Ltd

BiondVax Pharmaceuticals Ltd

BlueWillow Biologics Inc

Brandenburg Antiinfektiva GmbH

Celltrion Inc

Changchun Bcht Biotechnology Co Ltd

Chicago Biosolutions Inc

Cidara Therapeutics Inc

CSL Ltd

Emergent BioSolutions Inc

Ena Respiratory Pty Ltd

FluGen Inc

Gamma Vaccines Pty Ltd

ILiAD Biotechnologies LLC

Inovio Pharmaceuticals Inc

InvVax Inc

Jiangsu Ab&b Biotechnology Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Liaoning Cheng Da Biotechnology Co Ltd

Moderna Inc

NanoViricides Inc

New Amsterdam Sciences Inc

Novavax Inc

PrEP Biopharm Ltd

Sanofi

Seqirus Ltd

Serum Institute of India Pvt Ltd

Shanghai Institute of Biological Products Co Ltd

Trellis Bioscience Inc

Vacthera BioTech GmbH

Zosano Pharma Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H3N2 Subtype Infections – Overview

Influenza A Virus, H3N2 Subtype Infections – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H3N2 Subtype Infections – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H3N2 Subtype Infections – Companies Involved in Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections – Drug Profiles

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects

Influenza A Virus, H3N2 Subtype Infections – Discontinued Products

Influenza A Virus, H3N2 Subtype Infections – Product Development Milestones

Featured News & Press Releases

Mar 15, 2022: First Participants dosed in phase 2a study of pan-antiviral nasal spray

Jan 05, 2022: Zosano Pharma announces publication of clinical data demonstrating comparable immunogenicity of a Trivalent Influenza Vaccine formulated on its transdermal microneedle system versus an intramuscular injection of the vaccine at a higher dose

Aug 31, 2021: FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal) vaccine now available in the US for annual flu season

Aug 02, 2021: FluGen announces publication of positive results from phase 2 human challenge study of its M2SR vaccine candidate against highly drifted strain of H3N2 influenza virus

Jul 01, 2021: FluGen awarded US Department of Defense funding to conduct clinical study evaluating investigational M2SR flu vaccine and current standard-of-care high dose vaccine

May 25, 2021: FluGen initiates NIH-funded trial of M2SR flu vaccine; first study in adults up to age 85

Aug 13, 2020: AstraZeneca ships FLUMIST QUADRIVALENT Vaccine in the US for 2020-2021 Flu Season

Feb 25, 2020: Novavax’ Preclinical NanoFlu Data published in vaccines; details structural basis for broadly neutralizing immunity

Nov 04, 2019: Sanofi: FDA approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

Oct 16, 2019: Novavax begins Phase III clinical trial for influenza vaccine NanoFlu

Jun 27, 2019: Novavax confirms accelerated approval pathway available for licensure of Nanoflu

Feb 12, 2019: FluGen’s M2SR Influenza Vaccine succeeds in phase 2 human challenge trial against a highly mismatched virus

Jan 03, 2019: Novavax announces positive phase 2 NanoFlu results in older adults

Dec 05, 2018: Next generation cell-based influenza vaccine shows significantly greater effectiveness compared to standard egg-based options in the 2017-18 US Influenza Season

Nov 16, 2018: Seqirus announces U.S. $140 Million manufacturing expansion to meet growing demand for innovative cell-based influenza vaccines

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AbbVie Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Adimmune Corp, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Alla Chem LLC, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Allergy Therapeutics Plc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AlphaVax Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Ansun Biopharma Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Aphios Corp, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AstraZeneca Plc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AusBio Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by BlueWillow Biologics Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Brandenburg Antiinfektiva GmbH, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Celltrion Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Changchun Bcht Biotechnology Co Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Chicago Biosolutions Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Cidara Therapeutics Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by CSL Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Emergent BioSolutions Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Ena Respiratory Pty Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by FluGen Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Gamma Vaccines Pty Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by ILiAD Biotechnologies LLC, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by InvVax Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Jiangsu Ab&b Biotechnology Co Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Moderna Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by NanoViricides Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by New Amsterdam Sciences Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Novavax Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by PrEP Biopharm Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Seqirus Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Serum Institute of India Pvt Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Shanghai Institute of Biological Products Co Ltd, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Trellis Bioscience Inc, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Vacthera BioTech GmbH, 2022

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Zosano Pharma Corp, 2022

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects, 2022

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects, 2022 (Contd..1)

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects, 2022 (Contd..2)

Influenza A Virus, H3N2 Subtype Infections – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.